Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Extract Labs Review
A veteran-owned Colorado extractor that genuinely makes its own product — and sells a $99.99 capsule for appetite control on a mechanism whose only licensed drug was withdrawn for psychiatric harm.
Extract Labs
Real Manufacturer, Overreaching ClaimThe genuine strength: this is an actual manufacturer, not a relabeller. Founded in 2016 by Craig Henderson, an Army infantry veteran who served in Iraq, running its own extraction in Lafayette, Colorado, and selling bulk isolate — which is what a company that makes raw material does. The 60-day guarantee needs no return at all.
Checked on 8 August 2026 via the store's own product API: CBD oils $64.99–$144.99 by strength, capsules $94.99–$249.99, gummies $39.99–$69.99, bulk CBG isolate $295 and CBN isolate $490. Range spans CBD, CBG, CBN, CBC and THCV plus functional mushroom and kava lines.
The product that concerns us is THCV Capsules “Craving Control”, $99.99 for 60 capsules of 5mg THCV and 30mg CBG, sold to “support weight management” and “curb hunger”. THCV blocks the CB1 receptor. The last drug to reduce appetite that way was rimonabant, withdrawn in 2008-09 over depression and suicidality — and the capsule's 5mg sits below the 8-16mg used in the small studies that reported any weight change.
Affiliate disclosure: GLP1Drugs.org earns a commission if you buy through the links on this page. Live pricing was read from the store's own product API because the site blocks automated page access; policies and the recall notice were read from the site's own published pages. Verified 8 August 2026.
Visit Extract LabsOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
2016
Founded, Own Colorado Facility
5mg
THCV Per Capsule vs 8-16mg Studied
60
Day Guarantee, No Return Needed
3.1
Trustpilot, From Only 14 Reviews
What We Verified, Good And Bad
A real manufacturer and an overreaching claim, in the same company.
The Manufacturing Is Genuinely Real
Founded in 2016 by Craig Henderson, an Army infantry veteran who served in Iraq, and running its own extraction in Lafayette, Colorado. Vertical integration is rare in this category and it is the brand's strongest claim
'Craving Control' Is The Product To Question
$99.99 for 60 capsules of 5mg THCV plus 30mg CBG, sold to 'support weight management' and 'curb hunger'. That is an appetite claim, and appetite is this site's subject
THCV Blocks The Receptor THC Activates
THCV acts as a CB1 antagonist, the mirror image of THC's appetite stimulation. The mechanism is real pharmacology, not marketing invention — which is exactly why the precedent matters
The Last CB1 Drug Was Withdrawn
Rimonabant, a CB1 inverse agonist, was licensed for obesity in Europe in 2006 and withdrawn in 2008-09 over depression, anxiety and suicidal ideation. It was never approved in the US
The Dose Is Below The Studied Dose
The small human work reporting weight change used roughly 8mg to 16mg of THCV daily. One Craving Control capsule contains 5mg, so a single daily capsule sits under even the lower arm
There Was A Peanut Recall In August 2025
Extract Labs voluntarily recalled a batch of sugar-free mixed berry CBD gummies for potential undeclared peanut protein and undeclared colouring components, with FDA knowledge
Appetite Claims Against The Evidence
What each approach to appetite has actually demonstrated, in whom, and at what dose.
| Approach | Evidence | Result on weight | Status |
|---|---|---|---|
| Semaglutide 2.4mg | STEP 1, thousands of participants, randomised, placebo-controlled, 68 weeks | Mean 14.9% body-weight reduction vs 2.4% placebo | FDA-approved |
| Tirzepatide 15mg | SURMOUNT-1, randomised, placebo-controlled, 72 weeks | 20.9% vs 3.1% placebo | FDA-approved |
| Rimonabant (CB1) | Full drug development programme; licensed in Europe 2006 | Worked on weight — then caused depression, anxiety, suicidal ideation | Withdrawn 2008-09; never US-approved |
| THCV (this product) | Small preliminary human studies; ~44 participants at 8-16mg/day in the one reporting weight change | Preliminary only; an earlier diabetes trial improved glycaemia without weight loss | Supplement, 5mg/capsule |
The row that should give the most pause is the third one, because it is the only time this receptor has been targeted for appetite with a full development programme behind it. THCV is a neutral antagonist rather than an inverse agonist, and that difference is the genuine reason to think it may be safer — but nobody has run a trial large enough to show it. If appetite control is what you want, start with our provider rankings and our side-effects guide.
Pros & Cons
Pros
- ✓A genuine manufacturer, not a white-label reseller: founded 2016, running its own extraction facility in Lafayette, Colorado
- ✓Veteran-owned — founder Craig Henderson is a US Army infantry veteran who served in Iraq in 2004 and 2005
- ✓A 60-day money-back guarantee that requires no return at all: the company issues the refund and tells you to keep the product
- ✓Unusually broad cannabinoid range for one manufacturer — CBD, CBG, CBN, CBC and THCV, plus functional mushrooms and kava lines
- ✓Pricing is legible and mid-market: CBD oils $64.99 to $144.99 by strength, capsules $94.99 to $249.99, gummies $39.99 to $69.99
- ✓The August 2025 recall was voluntary, conducted with FDA knowledge, published with the affected batch number and still on the site a year later
- ✓Product descriptions state cannabinoid content per unit and per bottle rather than only a headline total
- ✓Bulk isolates are sold openly, which is consistent with a company that actually makes the raw material
Cons
- ✕The THCV 'Craving Control' capsule is sold to 'curb hunger' and 'support weight management' on human evidence that does not support a weight-loss claim
- ✕At 5mg THCV per capsule it is below the roughly 8-16mg daily doses used in the small human studies that reported any weight change
- ✕CB1 antagonism is the mechanism class of rimonabant, withdrawn in 2008-09 for depression, anxiety and suicidality — a precedent the product page does not mention
- ✕$99.99 for a 60-capsule bottle is a serious price for a cannabinoid with no adequate trial behind the claim
- ✕Subscriptions cannot be self-managed for auto-renewal: the policy states you 'are not able to turn on and off automatic renewals' from your subscription page
- ✕Pausing requires contacting a support representative, and if you are inside three days of renewal 'you will be charged'
- ✕The subscription policy states 'You may cancel your subscription 60 days from the start date', wording that reads as a minimum term
- ✕An August 2025 recall covered potential undeclared peanut protein — a life-threatening allergen — plus undeclared colouring components on the label
- ✕The recall response form rendered a submission error when we retrieved the page, which is the mechanism consumers are told to use
- ✕Of 27 edible products, 14 carried no peanut-facility statement in the description returned by the store's own API
- ✕Delta-8 and delta-9 edibles at 10mg to 33mg a piece cannot survive the 0.4mg per-container federal cap arriving 12 November 2026
- ✕Trustpilot holds just 3.1 out of 5 across only 14 reviews, and we found no BBB profile — very thin independent signal for a company operating since 2016
- ✕The site blocks automated access, so we could not open batch certificates to verify them ourselves
Our Verdict
3.3 / 5 — one of the more credible manufacturers in hemp, selling one product it should not be selling the way it sells it.
Extract Labs earns real credit on the things that are hardest to fake. It has made its own product since 2016 from its own extraction facility in Lafayette, Colorado, founded by an Army infantry veteran who served in Iraq. It sells bulk isolate, which is what companies that actually produce raw material do. Its 60-day money-back guarantee is better than most because it requires no return — you keep the bottle and the refund is issued. Pricing is legible and mid-market. And when it had a manufacturing problem in August 2025 it ran a voluntary recall with the FDA informed, named the batch, published instructions, and left the notice up a year later instead of deleting it. That is what accountability looks like.
The reservation is concentrated in one product and one policy. 'Craving Control' at $99.99 sells appetite suppression and weight management on evidence that cannot carry those words: a handful of small human studies, one of which improved glycaemic control without reducing weight, and another reporting weight change at 8mg to 16mg of THCV daily — above the 5mg in this capsule. The mechanism, CB1 blockade, is the one place a weight drug has already been licensed and withdrawn, rimonabant having been pulled in 2008-09 over depression, anxiety and suicidality. THCV being a neutral antagonist rather than an inverse agonist is a fair and real distinction in its favour; it is not a substitute for a trial. None of that appears on the product page.
The policy problem is the subscription. You cannot switch auto-renewal off from your own subscription page, pausing means contacting a representative, you are charged if you are inside three days of renewal, and the wording 'You may cancel your subscription 60 days from the start date' reads as a minimum term. Add a recall for undeclared peanut protein, a recall response form that returned an error when we fetched it, no peanut statement in the descriptions of 14 of 27 edibles, and Trustpilot at 3.1 from just 14 reviews, and 3.3 is where it settles. Buy the CBD, CBG and CBN as one-off purchases and it is a good brand. Skip the appetite capsule.
Visit Extract LabsFrequently Asked Questions
Does the THCV 'Craving Control' capsule actually suppress appetite?
The mechanism is real, the human evidence is not adequate, and the gap between those two things is the whole story. THCV — tetrahydrocannabivarin — acts as an antagonist at the CB1 receptor, which is the receptor delta-9 THC activates to produce the appetite stimulation everyone has heard of. Blocking it rather than activating it is a plausible route to reduced hunger, and this is established pharmacology rather than something invented for a label. What does not exist is the trial evidence a claim like 'curb hunger' would need. The human literature is sparse and mostly small: an early randomised study in type 2 diabetes found metabolic effects on glycaemic control without producing weight loss, and a more recent small study of THCV strips in around 44 participants over 90 days reported weight reduction at daily doses of roughly 8mg and 16mg THCV. That is preliminary work, not a basis for selling appetite control at $99.99 a bottle. Note also the arithmetic: Extract Labs' capsule contains 5mg of THCV, so one a day is below even the lower dose in the study that reported an effect. If you want a comparison, semaglutide 2.4mg produced a mean 14.9% body-weight reduction over 68 weeks in STEP 1, against placebo, in thousands of people. Nothing about THCV is in that evidentiary universe.
Is there a safety concern with a CB1 blocker?
There is a serious precedent, and it deserves stating carefully because the honest answer includes a genuine counterargument. The precedent is rimonabant, marketed as Acomplia. It was a CB1 inverse agonist licensed in Europe in 2006 for obesity, it worked on weight, and it was withdrawn in 2008 with the European regulator formally acting in January 2009, because of psychiatric adverse effects — depression, anxiety and suicidal ideation. It was never approved in the United States. That is the last time a drug was brought to market to reduce appetite by acting on this receptor, and it is not a reassuring history. The counterargument, which is real, is that rimonabant was an inverse agonist rather than a plain blocker, and researchers widely attribute its psychiatric effects to that inverse-agonist activity. THCV is generally characterised as a neutral CB1 antagonist, and a substantial line of research has pursued neutral antagonists specifically in the hope of separating the metabolic benefit from the mood harm. So THCV is not rimonabant and it would be wrong to say it is. But the reason anyone is interested in neutral antagonists at all is that the last compound acting here caused psychiatric harm, and nobody has run a trial large or long enough to establish that THCV avoids it. If you have any history of depression, anxiety or suicidal thoughts, this is a conversation to have with a clinician before buying an appetite product, not after.
Is Extract Labs a real manufacturer or a rebrand?
A real manufacturer, and this is the strongest thing about the company. Extract Labs was founded in 2016 by Craig Henderson, a US Army infantry veteran who saw combat in Iraq in 2004 and 2005, and it began as a garage operation before growing into its own extraction facility in Lafayette, Colorado, in the Boulder area. It runs its extraction in-house rather than buying finished goods and putting a label on them, which is genuinely uncommon in a category full of brands that are marketing companies with a contract manufacturer somewhere behind them. The evidence for vertical integration is not just the company's own telling: it sells bulk CBG and CBN isolate at $295 and $490, which is the behaviour of a business that makes raw material rather than one that buys it. The product range also supports it — CBD, CBG, CBN, CBC and THCV across tinctures, capsules, gummies, topicals and vapes, plus separate functional mushroom and kava lines, is a lot of formulation for a reseller. So on provenance and manufacturing this brand sits well above the category average, and our reservations are about specific claims and specific policies rather than about whether the company is real.
What happened with the recall?
In August 2025 Extract Labs voluntarily recalled a batch of its Sugar-Free Mixed Berry CBD Gummies, batch number 25E5082907, for two reasons: potential cross-contact with peanut protein, and undeclared ingredients on the label, specifically lycopene from red colouring and glycerine from red and violet colouring. The recall notice states it was conducted with the knowledge of the FDA, that the product had been distributed nationwide through the company's own site and retail partners, and that no illnesses or adverse events had been reported. Two things are true about this at once. Undeclared peanut protein in a food product is a serious failure — peanut is one of the major allergens precisely because reactions can be life-threatening, and someone with a peanut allergy relies entirely on the label. But the handling is what you would want: the recall was voluntary, it identified the specific batch, it was published with instructions and a contact number, it was done with the regulator informed, and the notice is still on the site a year later rather than quietly deleted. Many hemp companies would have handled this far worse. One caveat we should report: when we retrieved that page, the recall response form rendered a submission error rather than a working form, which is unfortunate for the one mechanism consumers are directed to use.
Are the gummies safe if I have a peanut allergy?
Assume not, and verify with the company before buying. The August 2025 recall was for potential peanut cross-contact, and the corrective disclosure that now appears on some product descriptions is the line 'Packaged in the same facility as peanuts.' That statement tells you what you need to know: this is a facility where peanuts are present, so cross-contact is a live possibility across the edible range rather than a problem confined to one batch. What we can report precisely is that of 27 edible products in the store's own product data, 13 carried a peanut statement in the description and 14 did not. We want to be careful about what that does and does not prove. We could not load the product pages themselves — the site blocks automated access — so a disclosure could well appear in an ingredients tab, on the packaging, or elsewhere on the page without appearing in the description field we could read. The physical label is what legally matters and we have not inspected it. But the inconsistency in the descriptions is real, and for a genuine peanut allergy the safe course is to contact Extract Labs and ask directly about the specific product and batch rather than relying on whether a particular page happens to mention it.
How does the subscription work, and can I get out of it?
This is the part of the operation we would most want tightened, and it is worth reading the policy rather than the marketing. Three provisions stand out, quoted from the company's own subscription policy. First: 'Through your subscription page, you are not able to turn on and off automatic renewals' — so the single control most people want is not self-service. Second: pausing requires contacting a support representative, can only be done four or more days ahead, and 'if the subscription date is within 3 days you will be charged'. Third, and most consequential: 'You may cancel your subscription 60 days from the start date', alongside 'Your subscription may not be cancelled 3 days prior to the subscription renewal date'. That first sentence reads naturally as a minimum term of 60 days before cancellation is available, though it is ambiguous enough that it could be intended to mean something looser. We are not going to resolve someone else's drafting for them — the point is that a policy governing recurring charges should not be ambiguous about when you are allowed to stop them. The policy also states that a failed payment triggers an automatic retry. If you subscribe, get the cancellation terms confirmed in writing first, and diary the renewal date yourself, because you cannot switch renewal off from your own account page.
Is the 60-day money-back guarantee real?
Yes, and it is one of the better ones we have read — with a list of exclusions you should know before relying on it. The mechanism is genuinely generous: you use the product consistently for two full weeks, and if it has not done anything you fill in a form and the company issues a refund with, in its words, 'no returns necessary'. Not having to ship a half-used bottle back is a real advantage over most guarantees in this category. The exclusions are where to read carefully. It covers one bottle of each SKU only. It excludes bulk raw materials, merchandise such as t-shirts and hoodies, vape batteries, and gift cards. It covers the cost of the product but not shipping, taxes or other fees. It does not apply to replacement items obtained from a previous guarantee claim, to samples, or to anything bought from a retailer other than Extract Labs directly — so a purchase made through a third-party store or marketplace is outside it. International orders are honoured subject to the same conditions with a stated exception. None of that is unreasonable, and the two-week trial requirement is fair. Just do not assume 'money back guarantee' extends to a shelf-clearing multi-bottle order, because it explicitly does not.
What about the delta-8 and delta-9 products?
They have a hard expiry date, and it is close. Extract Labs sells delta-8 gummies at around 33mg a piece with bottles up to 1,000mg, delta-9 gummies at 10mg a piece with 200mg bottles, low-dose delta-9 at 5mg, and a 10mg THC seltzer. All of that is currently sold as hemp under the 2018 Farm Bill. H.R. 5371, enacted on 12 November 2025 and effective on 12 November 2026, changes two things that matter here. It redefines the 0.3% limit to apply to total THC measured after decarboxylation and inclusive of THCA. And for finished consumable products it imposes a cap of 0.4 milligrams of total THC per innermost retail container. That second provision is the one that matters for edibles: a 200mg delta-9 bottle is five hundred times that cap, and a 1,000mg delta-8 bottle is two and a half thousand times it. There is no reformulation that keeps a 10mg gummy inside a 0.4mg container limit. So the intoxicating part of this catalogue has roughly three months of federal life left as we write on 8 August 2026. The CBD, CBG, CBN, CBC, mushroom and kava lines are not affected in the same way, because they are not sold on THC content. If you are buying the THC products, buy them understanding the date.
Should someone on a GLP-1 buy the Craving Control capsules?
We would not, and the reasoning is not squeamishness about supplements. If you are already taking a GLP-1 receptor agonist, appetite suppression is the mechanism you are already paying for, and it is being delivered by a medicine with large randomised trials behind it. Adding a $99.99 bottle of a cannabinoid whose appetite claim rests on preliminary studies at doses higher than the capsule contains is spending money to duplicate an effect you have already bought, with no evidence about the combination. Beyond redundancy, there are two specific reasons to raise it with a prescriber rather than just starting. The psychiatric history of CB1-acting weight drugs is genuinely unreassuring, and GLP-1 labelling already asks clinicians to monitor for depression and suicidal ideation and to be cautious in people with a psychiatric history — so stacking an unstudied CB1 antagonist on top complicates exactly the monitoring your prescriber is doing. And the capsule pairs THCV with 30mg of CBG, which means you are also taking a second cannabinoid at a meaningful dose. If your appetite is not adequately controlled on your current dose, the productive conversation to have is about your titration schedule, not about adding a second product on top of it.
Who is this brand right for?
It suits someone who wants CBD, CBG or CBN from a company that actually manufactures rather than relabels, values that it is veteran-owned and Colorado-based, and likes the fact that the 60-day guarantee does not require shipping anything back. On that basis Extract Labs is a reasonable choice and better provenance than much of the category. Buy the plain cannabinoid products, buy them one-off rather than on subscription until you have the cancellation terms in writing, and if you have a peanut allergy contact the company before ordering any edible. It suits poorly anyone shopping for weight management. The Craving Control capsule is the one product on this site that speaks directly to our readers, and it is the one we would tell you to skip: the claim outruns the evidence, the dose is below the studied dose, the mechanism has an unhappy regulatory history, and at $99.99 a bottle you are paying branded-medication money for preliminary science. And if you are buying the delta-8 or delta-9 edibles, understand you are buying into a category with a federal deadline in November 2026.
Buy The Cannabinoids, Skip The Appetite Capsule
A credible manufacturer worth using for CBD, CBG and CBN. The $99.99 'Craving Control' is the one product whose claim outruns its evidence.
Visit Extract LabsCompare Other GLP-1 Providers
See how other telehealth providers stack up.
CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Amazon One Medical
Brand-Name, No CompoundingFDA-approved Wegovy, Zepbound and Foundayo from $149/month cash, $25 with insurance and $50/month for eligible Medicare members — the first mainstream route to approved medication at prices that compete with compounded. We earn no commission from it
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →Medical Disclaimer: This page is informational and is not medical advice. These are dietary supplements and hemp products, not medicines; they are not intended to diagnose, treat, cure or prevent any disease and are not a substitute for prescribed treatment. Never stop, delay or alter a prescribed medication in favour of a supplement. THCV acts at the CB1 cannabinoid receptor; rimonabant, a CB1 inverse agonist licensed for obesity in Europe in 2006, was withdrawn in 2008-09 following reports of depression, anxiety and suicidal ideation, and anyone with a history of depression, anxiety, self-harm or suicidal thoughts should consult a clinician before taking any CB1-acting product. GLP-1 receptor agonist labelling advises monitoring for depression and suicidal ideation, so tell your prescriber about any cannabinoid product you take. Delta-8 and delta-9 THC products are intoxicating, are for adults 21 and over where permitted, can impair driving and can produce a positive drug test. Extract Labs products are packaged in a facility where peanuts are present and a batch was recalled in August 2025 for potential undeclared peanut protein; anyone with a peanut allergy should contact the company before consuming any edible. Consult a licensed clinician before starting or changing treatment.
Date reviewed: 8 August 2026. The site blocks automated page access behind a Cloudflare challenge, so prices and product details were read from the store's own public WooCommerce product API on that date, and policy and recall text from the site's own published pages via its WordPress API; figures may change. THCV Capsules 'Craving Control' were listed at $99.99 with the description stating 5mg THCV and 30mg CBG per capsule, 60 capsules per bottle, 'designed to boost energy, support weight management, enhance focus, and curb hunger'. THCV Gummies were $49.99 at 10mg THCV plus 10mg CBD per gummy. Other listed prices included CBD oils $64.99–$144.99, capsules $94.99–$249.99, gummies $39.99–$69.99, bulk CBG isolate $295 and bulk CBN isolate $490. Delta-8 gummies were listed around 33mg per piece up to 1,000mg per bottle, delta-9 gummies at 10mg per piece and 200mg per bottle, low-dose delta-9 at 5mg, and a THC seltzer at 10mg. Subscription quotations are from the company's Subscription Policy page, including 'Through your subscription page, you are not able to turn on and off automatic renewals', 'if the subscription date is within 3 days you will be charged', 'You may cancel your subscription 60 days from the start date' and 'Your subscription may not be cancelled 3 days prior to the subscription renewal date'. Guarantee terms and exclusions are from the company's 60-Day Money Back Guarantee page. The recall notice, dated 26 August 2025, covers Sugar-Free Mixed Berry CBD Gummies batch #25E5082907 for potential peanut cross-contact and undeclared lycopene and glycerine colouring components, states it was conducted with the knowledge of the FDA and that no illnesses or adverse events had been reported; the recall response form rendered a submission error when we retrieved the page. Of 27 edible products, 13 carried a peanut-facility statement in the description field returned by the API and 14 did not — we could not load the product pages themselves, so a disclosure may appear elsewhere on them or on the physical label. Company background — founded 2016 by Craig Henderson, US Army infantry veteran who served in Iraq in 2004 and 2005, with extraction in Lafayette, Colorado — is from press coverage and the company's own account. Rimonabant was licensed in Europe in 2006 and withdrawn in 2008 with the European regulator acting in January 2009; it was never FDA-approved. STEP 1 and SURMOUNT-1 figures are as published. Trustpilot showed 3.1 out of 5 across 14 reviews; a BBB search returned no profile. H.R. 5371 was enacted 12 November 2025 and takes effect 12 November 2026, applying the 0.3% limit to total THC after decarboxylation inclusive of THCA and capping finished consumable products at 0.4mg total THC per innermost retail container. We could not open batch certificates of analysis because of the access block, so we neither verified nor dispute them.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This does not influence our editorial content or review ratings.